AKERO THERAPEUTICS 00973Y108 US00973Y1082 12/02/2025 To consider and vote on the proposal to approve, by non-binding, advisory vote, compensation that may be paid or become payable by Akero to its named executive officers in connection with the Merger (we refer to this proposal as the "Compensation Proposal"). SECTION 14A SAY-ON-PAY VOTES ISSUER 5733989 0 FOR 5733989 FOR ALKAMI 01644J108 US01644J1088 05/19/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers, or NEOs. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 19379038 NONE CENTESSA PHARMACEUTICALS 152309100 US1523091007 06/12/2026 To receive and approve, on an advisory basis, the Company's UK statutory directors' remuneration report for the financial year ended December 31, 2025, which is set forth as "Annex A" to the attached proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1354830 0 FOR 1354830 FOR CONTEXTLOGIC INC 21077C305 US21077C3051 06/11/2026 To approve, on an advisory basis, our named executive officer compensation for the year ended December 31, 2025, as disclosed herein (the "Compensation Proposal"). SECTION 14A SAY-ON-PAY VOTES ISSUER 609616 0 FOR 609616 FOR CHIME 16935C109 US16935C1099 06/02/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 21259683 NONE CHIME 16935C109 US16935C1099 06/02/2026 To select, on a non-binding advisory basis, whether future advisory votes on the compensation of our named executive officers should be held every one, two, or three years. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 21259683 NONE NURIX THERAPEUTICS 67080M103 US67080M1036 05/15/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 3032185 NONE REVOLUTION MEDICINES 76155X100 US76155X1000 06/18/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission;("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 ABSTAIN 357791 NONE